公开(公告)号：US20210148904A1

公开(公告)日：2021-05-20

申请号：US16611563

申请日：2018-05-08

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Seok-Joon Kwon ,  Jonathan Seth Dordick ,  Domyoung Kim ,  Jungbae Kim ,  Inseon Lee

IPC: G01N33/543 ,  G01N33/569 ,  C12Q1/26 ,  C12Q1/6851 ,  C12Q1/689

Abstract: Methods and systems are directed to multiplex detection of a bacterial pathogen in a sample. A first biotinylated lysin-derived cell wall binding domain is complexed with an avidin layer on a surface. A first bacterial pathogen detection complex including a second biotinylated lysin-derived cell wall binding domain, a detection domain, and an avidin linker complexed between the cell wall binding domain and the detection domain is also provided. The cell wall binding domains are derived from an endolysin, autolysin, bacteriocin, or exolysin, and are configured to bind a cell wall of a target bacterial pathogen. The detection domain includes one or more enzymes, fluorescent material, or DNA for emitting a signal for detection. Target bacterial pathogens present in a sample can thus be detected in a sandwich assay exhibiting increased selectivity and reduced limit of detection relative to traditional ELISA.

公开(公告)号：US20250114394A1

公开(公告)日：2025-04-10

申请号：US18597050

申请日：2024-03-06

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert John LINHARDT ,  So-Young Kim ,  Weihua Jin ,  Jonathan Seth Dordick ,  Fuming Zhang ,  Seok-Joon Kwon ,  Paul S. Kwon ,  Keith Fraser

IPC: A61K31/727 ,  A61K31/737 ,  A61K45/06 ,  A61P31/04

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

公开(公告)号：US20250090572A1

公开(公告)日：2025-03-20

申请号：US18899285

申请日：2024-09-27

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert John LINHARDT ,  So-Young Kim ,  Weihua Jin ,  Jonathan Seth Dordick ,  Fuming Zhang ,  Seok-Joon Kwon ,  Paul S. Kwon ,  Keith Fraser

IPC: A61K31/737 ,  A61K31/727 ,  A61P31/14

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

公开(公告)号：US20240402161A1

公开(公告)日：2024-12-05

申请号：US18810823

申请日：2024-08-21

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Seok-Joon KWON ,  Jonathan Seth Dordick ,  Domyoung KIM ,  Jungbae KIM ,  Inseon LEE

IPC: G01N33/543 ,  C12Q1/26 ,  C12Q1/6851 ,  C12Q1/689 ,  G01N33/569

Abstract: Methods and systems are directed to multiplex detection of a bacterial pathogen in a sample. A first biotinylated lysin-derived cell wall binding domain is complexed with an avidin layer on a surface. A first bacterial pathogen detection complex including a second biotinylated lysin-derived cell wall binding domain, a detection domain, and an avidin linker complexed between the cell wall binding domain and the detection domain is also provided. The cell wall binding domains are derived from an endolysin, autolysin, bacteriocin, or exolysin, and are configured to bind a cell wall of a target bacterial pathogen. The detection domain includes one or more enzymes, fluorescent material, or DNA for emitting a signal for detection. Target bacterial pathogens present in a sample can thus be detected in a sandwich assay exhibiting increased selectivity and reduced limit of detection relative to traditional ELISA.

公开(公告)号：US12099057B2

公开(公告)日：2024-09-24

申请号：US16611563

申请日：2018-05-08

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Seok-Joon Kwon ,  Jonathan Seth Dordick ,  Domyoung Kim ,  Jungbae Kim ,  Inseon Lee

IPC: G01N33/543 ,  C12Q1/26 ,  C12Q1/6851 ,  C12Q1/689 ,  G01N33/569

CPC classification number: G01N33/54306 ,  C12Q1/26 ,  C12Q1/6851 ,  C12Q1/689 ,  C12Y101/03004 ,  G01N33/56911

Abstract: Methods and systems are directed to multiplex detection of a bacterial pathogen in a sample. A first biotinylated lysin-derived cell wall binding domain is complexed with an avidin layer on a surface. A first bacterial pathogen detection complex including a second biotinylated lysin-derived cell wall binding domain, a detection domain, and an avidin linker complexed between the cell wall binding domain and the detection domain is also provided. The cell wall binding domains are derived from an endolysin, autolysin, bacteriocin, or exolysin, and are configured to bind a cell wall of a target bacterial pathogen. The detection domain includes one or more enzymes, fluorescent material, or DNA for emitting a signal for detection. Target bacterial pathogens present in a sample can thus be detected in a sandwich assay exhibiting increased selectivity and reduced limit of detection relative to traditional ELISA.